allosteric modulator development

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Its lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator), is under evaluation for brain injury recovery including post-stroke and traumatic brain injury. It also advances GABAB PAM programs for substance use disorders and chronic cough, and holds a 20% equity interest in Neurosterix LLC.

Read more

clinical-stage pharmaceutical researchdrug development